Targeting the Carotid Body Function With Big-K⁺-Channel Blocker ENA-001 in Opioid-Induced Respiratory Depression: A...

Area of Science:

• Anesthesiology
• Pharmacology
• Respiratory Medicine

Background:

• Opioids, anesthetics, and illicit drugs can cause life-threatening respiratory depression by affecting central respiratory networks.
• ENA-001 is a potential countermeasure that modulates ventilation via carotid bodies, aiming to avoid side effects like impaired analgesia or hypnosis.

Purpose of the Study:

• To conduct a literature review evaluating the efficacy and safety of ENA-001 as a respiratory stimulant and a reversal agent for drug-induced respiratory depression.

Main Methods:

• A scoping review of literature from in vitro, animal (mice, rats, non-human primates), and human volunteer studies.
• Literature search across multiple electronic databases for studies on ENA-001's respiratory effects.

Main Results:

• ENA-001 increased ventilation and reduced respiratory depression caused by morphine and xylazine-fentanyl combinations.
• In humans, ENA-001 enhanced minute ventilation and reduced end-tidal carbon dioxide; it improved ventilation and restored hypoxic response in models of alfentanil- and propofol-induced depression without affecting sedation or analgesia.
• The primary mechanism involves the carotid bodies, specifically the KCa1.1 (BK) channel's α-subunit. Safety profile was favorable with no serious adverse events.

Conclusions:

• ENA-001 is a first-in-class, peripherally acting respiratory stimulant.
• It effectively reverses drug-induced respiratory depression, supporting its clinical development for opioid- and anesthetic-induced respiratory compromise.